To assess the effects of pravastatin on all-cause mortality and cause-specific mortality and to compare the effects for patients with prior coronary heart disease with those for patients without, using pooled data from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, the Cholesterol and Recurrent Events (CARE) study, and the West of Scotland Coronary Prevention Study (WOSCOPS).
Introduction
Epidemiological studies have provided strong evidence of a continuous association between cholesterol concentration and the risk of subsequent coronary heart disease events [1, 2] . Early trials using treatments with modest effects on lipids had shown significant reductions in such events [2, 3] . However, the effect of treatment on mortality had remained uncertain, particularly for patients with average or below-average cholesterol levels, and for patients with a history of coronary heart disease.
Large-scale trials have now evaluated the effects of HMG-CoA reductase inhibitors across a broad spectrum of patients with or without elevated cholesterol levels and with or without a history of coronary heart disease [4] [5] [6] [7] [8] . Three of these trials used common trial designs and the same treatment, pravastatin [5] [6] [7] . The Prospective Pravastatin Pooling project, initiated in 1992, was designed to provide more reliable estimates of pravastatin treatment on all-cause mortality, coronary heart disease mortality, and total coronary heart disease events in different populations by pooling the data from three large-scale trials: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, [7] the Cholesterol and Recurrent Events (CARE) study [6] and the West of Scotland Coronary Prevention Study (WOSCOPS) [5] . Collectively, these studies provided data on 19 768 patients, 106 131 person-years of follow-up and 1748 deaths. This paper describes the effects of treatment on all-cause and causespecific mortality according to pre-specified objectives [9] .
Design and methods

Study design
The overall project aim was to assess the effect of pravastatin on mortality, coronary heart disease morbidity and other specific events, overall and within important subgroups. This paper reports the effects on total mortality and cause-specific mortality and examines the consistency of these effects across the constituent trials. The objectives included determining the effect of pravastatin therapy on all-cause mortality in the secondary prevention trials (LIPID and CARE), and in the three trials combined (LIPID, CARE and WOSCOPS), as well the effect of pravastatin therapy on cause-specific mortality for all three trials. The three studies were selected for inclusion because of their common design features and the closeness of their completion dates. Each study was a randomized, double-blind, placebo-controlled, clinical trial lasting approximately 5 years or more, using a dose of 40 mg pravastatin once daily. LIPID was a secondary prevention trial involving 9014 men and women with a history of myocardial infarction or hospitalization for unstable angina and total cholesterol at enrolment in the range <5·5  <213  43  56  0  31  5·5-6·4  213-249  40  44  16  33  d6·5  d250  17  0  84  36  LDL cholesterol  <3·5  <135  30  42  0  22  3·5-4·4  135-174  50  58  17  41  d4·5  d175  20  0  83  37  HDL cholesterol  <1·0  <39  63  57  31  51  d1·0  d39  37  43  69  49  Triglycerides  <1·5  <133  45  42  39  42  1·5-2·4  133-219  37  43  43  41  d2·5  d220  18  15 
Outcomes
Cause-specific mortality Three categories of fatal secondary cardiovascular outcomes were studied: fatal coronary heart disease (due to definite or possible myocardial infarction, sudden death, or other coronary heart disease); other fatal cardiovascular disease (stroke or other vascular disease); and any fatal cardiovascular disease (including coronary heart disease). Non-cardiovascular mortality was described separately as total and cause-specific non-cardiovascular diseases. Specific categories of non-cardiovascular fatal outcomes were: cancer mortality; trauma mortality (accidental death and suicide); and other noncardiovascular mortality. Cause-specific mortality was examined for all patients, for those with prior myocardial infarction or unstable angina (LIPID and CARE), and for those without coronary heart disease (WOSCOPS). Definitions and classification of all outcomes were agreed upon prospectively by the Prospective Pravastatin Pooling Project Steering Committee and incorporated in the full protocol [9] .
Analysis plan
All analyses were on an intention-to-treat basis, with primary analyses stratified by trial but unadjusted for other covariates. Analyses adjusted for patient covariates used the Cox proportional-hazards regression model. Mortality plots used Kaplan-Meier estimates. Relative risks were estimated from the hazard ratio, and heterogeneity of treatment effects across study populations was examined using tests for study-treatment interaction in the proportional-hazards model. In addition, a model based on a weighted combination of the effects seen on each specific cause of death was developed, enabling estimation of an 'expected' net 
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mortality reduction for any given risk population. Based on the proportions of different types of deaths in each trial, this enabled more robust reductions in total mortality to be estimated.
Project organization
The project steering committee was established in 1992, with representatives from all three trials, an epidemiologist and a chairman. A study protocol was finalized in July 1995, before any results of treatment from any of the three trials were known [9] . An individual patient data set was created for each trial, which enabled time-toevent outcomes and individual patient covariates to be examined. The sponsor supported the collaboration and the pooling of the trial data, but all analyses and assessment of the results were conducted independently of the sponsor.
Results
Study populations
The mean age at baseline was 59 years; 24% were aged 65 years or older (Table 1) . Women on average were 4·5 years older than men, primarily owing to the inclusion criteria for the trials contributing the data.
More than 2000 participants were women, all from the secondary prevention trials. Half of the participants had a prior myocardial infarction, and two-thirds had a history of coronary heart disease. Participants in WOSCOPS, almost all without documented coronary heart disease, had significantly higher lipid levels and were more often current smokers, but WOSCOPS had the lowest prevalence of diabetes and hypertension. LIPID and CARE were both restricted to patients with coronary heart disease and were similar in profile. Baseline factors were well balanced according to randomized treatment.
Treatment and follow-up
The mean study duration was 4·9 years for WOSCOPS, 5·0 years for CARE and 6·0 years for LIPID. Among patients allocated pravastatin, 18% had discontinued therapy at 5 years. Among those allocated placebo, 13% had commenced active lipid-lowering therapy at 5 years. Higher rates of discontinuation occurred in the WOSCOPS study of patients without known coronary heart disease, whereas higher rates of commencing active therapy occurred in LIPID, where a patient's standard care (including adding lipid therapy) was left to the patient's usual doctor (Table 2 ). Percentage changes in lipid levels relative to baseline between treatment groups are also provided. Among those assigned pravastatin, there was a 0·97 mmol . l 1 greater average decrease in cholesterol over 5 years (compared with placebo), 0·94 mmol . l 1 decrease in LDL cholesterol, 0·05 mmol . l 1 increase in HDL cholesterol and 0·18 mmol . l 1 decrease in triglycerides. By comparison, among patients who received their allocated treatment for 5 years, the average differences with treatment were 1·07, 1·03, 0·06 and 0·20 mmol . l 1 , respectively. *Not included in the original publication [5] . CHD=coronary heart disease; MI=myocardial infarction; CVD=cardiovascular disease.
Total mortality
Effects of treatment on total mortality are shown in Figs 1 and 2. For the three trials combined, there was a significant reduction in total mortality of 20% (95% CI 12-27%). The relative reduction in total mortality in the secondary prevention trials (LIPID and CARE) combined, at 19%, was similar to that seen in WOSCOPS, at 22%. Mortality curves begin to diverge at some point after 6 months, with possibly larger effects seen later. However, tests for non-proportionality of hazards were not significant, consistent with a similar relative reduction in risk for each year on study. The actuarial risk of death at 5 years was reduced from 9·9% to 8·7% for LIPID and CARE combined, compared with 4·1% to 3·2% in WOSCOPS (Fig. 2) .
Cause-specific mortality
Causes of death for patients are detailed in Table 3 . Death from coronary heart disease accounted for 56% of deaths (58% in those with prior coronary heart disease and 44% in those without). The principal cause of coronary heart disease death in each of the three trials was sudden cardiac death. Deaths from stroke accounted for 4% of all deaths. The principal cause of non-cardiovascular death was cancer (26% of all deaths).
Pravastatin significantly reduced coronary heart disease mortality by 24% (95% CI 14-33%, P<0·0001) with risk reductions in coronary heart disease mortality seen among patients with prior coronary heart disease (23%) and those without (34%) (Fig. 1) . Coronary heart 
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disease mortality curves diverged at about 2 years in patients with prior coronary heart disease ( Fig. 2, panel  3 ), but a test for non-proportionality of hazards was not statistically significant. The actuarial risk of death from coronary heart disease at 5 years was reduced from 6·0% to 4·9% for LIPID and CARE combined, compared with 1·8% to 1·2% in WOSCOPS. There was a nonsignificant decrease in other cardiovascular deaths of 17% (95% CI 14-40%, P=0·25). When all cardiovascular deaths are combined (coronary heart disease and other cardiovascular deaths), treatment significantly reduced cardiovascular mortality by 24% (95% CI 14-32%). There were separate statistically significant reductions in cardiovascular mortality in patients with prior coronary heart disease (P<0·0001) and those without (P=0·04). There was no significant increase in the number of deaths from cancer, trauma or suicide, or other nonvascular causes. Overall, there was a non-significant 12% decrease in deaths from non-cardiovascular causes (95% CI 3-25%, P=0·10). 
Effects of treatment on mortality within major subgroups
Effects of treatment on total and coronary heart disease mortality within subgroups of age, sex and qualifying event are detailed in Table 4 . No significant difference in the relative effects of treatment were found across any of these subgroups. There was a separately significant reduction in total mortality among patients 65 years or older (P<0·001), among men (P<0·001) and among patients with prior myocardial infarction (P=0·002) and with unstable angina (P=0·004).
Size of treatment effect
Treatment effect on total mortality was estimated for patients with prior myocardial infarction, with prior unstable angina but no myocardial infarction, and patients with no prior coronary heart disease, based on the assumption of a common relative risk reduction for each cause-specific mortality (Table 5 ). In this model the relative risk reduction for total mortality was similar for each patient group, but the absolute risk of death over 5 years was considerably higher among patients with a history of prior myocardial infarction or unstable angina than for patients without a history. Consequently, the numbers needed to treat to prevent a death were significantly lower among patients with prior coronary heart disease than those without.
The absolute benefits of treatment may be underestimated in this intention-to-treat analysis by about 18% owing to some patients discontinuing active treatment and to some patients allocated placebo starting active treatment. all-cause mortality for LIPID and CARE combined (patients with prior coronary heart disease) and for WOSCOPS (patients without prior coronary heart disease). Panel 2: all-cause mortality for the three trials combined. Panel 3: coronary heart disease mortality for LIPID and CARE combined and for WOSCOPS. Panel 4: coronary heart disease mortality for the three trials combined.
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Discussion
The combined results of LIPID, CARE and WOSCOPS provide consistent and convincing evidence of reductions in coronary and total mortality with pravastatin in a broad spectrum of patients. There are separately significant reductions in total mortality in patients with prior myocardial infarction or prior unstable angina across a broad range of cholesterol levels, as well as some evidence of reduction in patients without a history of coronary heart disease but with elevated cholesterol levels.
The reduced risk for total mortality is due principally to the reduction in deaths from coronary heart disease but may also be related to some reduction in other cardiovascular deaths, such as deaths from stroke. The estimated effect of treatment on non-cardiovascular deaths was not significant, but the observed number of such deaths was somewhat lower in patients allocated pravastatin. This finding may be due to chance but does provide some reassurance of treatment safety regarding non-cardiovascular deaths over the study period. There is also the possibility that pravastatin causes a modest true reduction in non-cardiovascular deaths, for example, by preventing underlying cardiovascular disease otherwise contributing to deaths from other causes.
While a similar relative reduction in coronary heart disease mortality was observed across the three trials and major subgroups, the power to demonstrate moderate differences in mortality reduction was low. It is more reliable to examine treatment effects across patient subgroups, using the more frequent end-point of fatal coronary heart disease plus non-fatal myocardial infarction. Using this end-point across pre-defined subgroups we showed, for the most part, consistent relative effects of treatment according to age, sex, coronary risk factors and lipid levels [10] . In addition, the data presented here support mortality reductions from treatment separately in both primary and secondary prevention settings, in both young and old, and in patients with prior myocardial infarction or unstable angina.
This prospective combined analysis has examined the effect of one specific cholesterol-lowering drug, pravastatin. Other HMG-CoA reductase inhibitors (or statins) have also been shown to significantly reduce coronary events to a similar degree in a range of patient populations. The Scandinavian Simvastatin Survival Study (4S) [4] convincingly showed significant reductions in total mortality with simvastatin in patients with prior coronary heart disease and an elevated baseline cholesterol level (5·5-8·0 mmol . l 1 ). The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS) [8] trial showed a significant reduction in coronary events with lovastatin in a primary prevention setting. The results from these trials, together with the pravastatin trials, are consistent with evidence of benefit across a broad spectrum of patients and broad range of initial cholesterol levels. The extent to which benefits of treatment are related to specific drugs, class effects or the change in lipid levels achieved is still unclear. Meta-analyses of trials using a range of cholesterollowering treatments have shown evidence of benefit in a variety of settings, with larger effects associated with treatments (such as the statins) that produce larger changes in lipids [11] . Pravastatin was associated predominantly with a reduction in LDL cholesterol, but to a lesser extent also improved lipid profiles through an increase in HDL cholesterol and a reduction in triglycerides. The results of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention provide some indirect evidence that changing the other lipid levels may also be important [12] . Here, treatment with gemfibrozil, in patients with prior myocardial infarction, increased HDL cholesterol and reduced triglycerides, without changing LDL cholesterol, and resulted in a significant reduction in coronary events.
While the benefits of pravastatin treatment may be consistent just with changes in lipids, effects of therapy through a variety of mechanisms are also plausible [13] . Some, but not all, of these may be mediated through lipid changes. Mechanisms in addition to long-term reduction in atherosclerosis include plaque stabilization, improvement in endothelium and vascular reactivity, reduced lipid oxidation and reduced thrombotic tendency.
The prospective design of this combined analysis provides several important advantages over a retrospective meta-analysis. Prospective meta-analysis provides a powerful, scientifically rigorous approach to combining trial evidence [14, 15] and the Cochrane Collaboration has now established a registry for future prospective metaanalyses. A further prospective overview of all major cholesterol trials is also planned by the Cholesterol Treatment Trialists' (CTT) Collaboration [14] . This prospective overview will include data from all recent and ongoing randomized, large-scale trials of cholesterol treatment and provide a broader overview of cholesterol treatment.
The scientific rationale for combining these three trials was based on the common design features, identical therapies and standardized outcomes. Combining trials evaluating treatment for patients with a history of coronary heart disease (LIPID and CARE) and without (WOSCOPS) was considered appropriate in that similar relative reductions in cause-specific mortality were expected. It was recognized that the effect of treatment on total mortality might vary because of the different proportions of coronary heart disease deaths in each trial. However, the model (using a common relative risk reduction for each cause-specific mortality) estimated similar relative effects on total mortality due to a similar proportion of coronary heart disease deaths among patients with and without coronary heart disease. This may reflect that the WOSCOPS population represented a group at higher risk than the general population. WOSCOPS patients were all male, had significantly elevated baseline cholesterol levels and were often smokers. However, they were still at lower risk of death from any cause than patients with a history of coronary heart disease. Consequently, there is still a much larger absolute benefit in terms of deaths prevented in treating patients with a history of coronary heart disease (even with average cholesterol levels) than in treating those without coronary heart disease (even with elevated cholesterol levels).
Although pravastatin had less absolute benefit for patients without prior coronary heart disease in preventing death, therapy had significant value in preventing a range of fatal and non-fatal cardiovascular events (including myocardial infarction, unstable angina and coronary revascularization). In WOSCOPS, treatment of 1000 patients over 5 years helped prevent more than 30 major cardiovascular events. Within WOSCOPS, greater absolute benefits of treatment were estimated among those at highest risk of a major coronary event with treatment considered cost-effective if applied to that 40% of WOSCOPS subjects at highest coronary heart disease risk [16] . Individually, each of the three trials reported a high safety profile for pravastatin and collectively there was no increase in fatal adverse events over at least 5 years of follow-up. Since any long-term adverse effects of therapy, such as new cancers, require even longer follow-up, there are plans to continue following patients in WOSCOPS and LIPID [5, 7] It is important that similar long-term safety profiles are obtained for other lipid-lowering therapies before these treatments become routine, particularly for lower-risk populations.
In conclusion, there is now good evidence of survival benefit without evidence of harm from 5 years of pravastatin therapy for patients both with and without established coronary heart disease. Therapy with such good evidence of benefit and safety should be considered for a broad cross-section of patients at sufficient risk of death from coronary heart disease.
